{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:41:37Z","timestamp":1764603697062,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Bone Marrow Cancer Trust"},{"DOI":"10.13039\/501100002101","name":"Division of Health Sciences, University of Otago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002101","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mackenzie Charitable Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00262-020-02636-2","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T14:03:11Z","timestamp":1592402591000},"page":"2453-2464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-367X","authenticated-orcid":false,"given":"Barry D.","family":"Hock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith L.","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Strother","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Goddard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Butt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret J.","family":"Currie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"issue":"6382","key":"2636_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"issue":"1","key":"2636_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40425-019-0586-0","volume":"7","author":"J Davda","year":"2019","unstructured":"Davda J, Declerck P, Hu-Lieskovan S, Hickling TP, Jacobs IA, Chou J et al (2019) Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. J Immunother Cancer 7(1):105\u2013114. https:\/\/doi.org\/10.1186\/s40425-019-0586-0","journal-title":"J Immunother Cancer"},{"issue":"21","key":"2636_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2016.00021","volume":"7","author":"M Krishna","year":"2016","unstructured":"Krishna M, Nadler SG (2016) Immunogenicity to biotherapeutics\u2014the role of anti-drug immune complexes. Front Immunol 7(21):1\u201313. https:\/\/doi.org\/10.3389\/fimmu.2016.00021","journal-title":"Front Immunol"},{"issue":"500","key":"2636_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aat1479","volume":"11","author":"F Jonsson","year":"2019","unstructured":"Jonsson F, de Chaisemartin L, Granger V, Gouel-Cheron A, Gillis CM, Zhu Q et al (2019) An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis. Sci Transl Med 11(500):1\u201314. https:\/\/doi.org\/10.1126\/scitranslmed.aat1479","journal-title":"Sci Transl Med"},{"issue":"1","key":"2636_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s40425-019-0663-4","volume":"7","author":"MJH van Vugt","year":"2019","unstructured":"van Vugt MJH, Stone JA, De Greef R, Snyder ES, Lipka L, Turner DC et al (2019) Immunogenicity of pembrolizumab in patients with advanced tumors. J Immunother Cancer 7(1):212. https:\/\/doi.org\/10.1186\/s40425-019-0663-4","journal-title":"J Immunother Cancer"},{"key":"2636_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2018.11.002","author":"PEH Jensen","year":"2019","unstructured":"Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C et al (2019) Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. J Neuroimmunol. https:\/\/doi.org\/10.1016\/j.jneuroim.2018.11.002","journal-title":"J Neuroimmunol"},{"key":"2636_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.09.002","author":"B El Osta","year":"2017","unstructured":"El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC (2017) Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.09.002","journal-title":"Crit Rev Oncol Hematol"},{"key":"2636_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.02.003","author":"TK Eigentler","year":"2016","unstructured":"Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grunwald V et al (2016) Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.003","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"2636_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-018-0095-z","volume":"4","author":"XY Wang","year":"2019","unstructured":"Wang XY, Wang B, Wen YM (2019) From therapeutic antibodies to immune complex vaccines. NPJ Vaccines 4(2):1\u20138. https:\/\/doi.org\/10.1038\/s41541-018-0095-z","journal-title":"NPJ Vaccines"},{"issue":"1","key":"2636_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12334","volume":"268","author":"JF Swisher","year":"2015","unstructured":"Swisher JF, Feldman GM (2015) The many faces of FcgammaRI: implications for therapeutic antibody function. Immunol Rev 268(1):160\u2013174. https:\/\/doi.org\/10.1111\/imr.12334","journal-title":"Immunol Rev"},{"issue":"6176","key":"2636_CR11","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","volume":"343","author":"CA Diebolder","year":"2014","unstructured":"Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA et al (2014) Complement is activated by IgG hexamers assembled at the cell surface. Science 343(6176):1260\u20131263. https:\/\/doi.org\/10.1126\/science.1248943","journal-title":"Science"},{"issue":"7","key":"2636_CR12","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1021\/acs.nanolett.9b02220","volume":"19","author":"J Strasser","year":"2019","unstructured":"Strasser J, de Jong RN, Beurskens FJ, Wang G, Heck AJR, Schuurman J et al (2019) Unraveling the macromolecular pathways of IgG oligomerization and complement activation on antigenic surfaces. Nano Lett 19(7):4787\u20134796. https:\/\/doi.org\/10.1021\/acs.nanolett.9b02220","journal-title":"Nano Lett"},{"issue":"292","key":"2636_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00292","volume":"10","author":"X Chen","year":"2019","unstructured":"Chen X, Song X, Li K, Zhang T (2019) FcgammaR-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy. Front Immunol 10(292):1\u201313. https:\/\/doi.org\/10.3389\/fimmu.2019.00292","journal-title":"Front Immunol"},{"issue":"1","key":"2636_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nri.2017.97","volume":"18","author":"ES Reis","year":"2018","unstructured":"Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD (2018) Complement in cancer: untangling an intricate relationship. Nat Rev Immunol 18(1):5\u201318. https:\/\/doi.org\/10.1038\/nri.2017.97","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"2636_CR15","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1182\/blood-2015-09-625343","volume":"127","author":"SA Beers","year":"2016","unstructured":"Beers SA, Glennie MJ, White AL (2016) Influence of immunoglobulin isotype on therapeutic antibody function. Blood 127(9):1097\u20131101. https:\/\/doi.org\/10.1182\/blood-2015-09-625343","journal-title":"Blood"},{"issue":"7","key":"2636_CR16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/eji.201847924","volume":"49","author":"S Dudek","year":"2019","unstructured":"Dudek S, Weissmuller S, Anzaghe M, Miller L, Sterr S, Hoffmann K et al (2019) Human Fcgamma receptors compete for TGN1412 binding that determines the antibody\u2019s effector function. Eur J Immunol 49(7):1117\u20131126. https:\/\/doi.org\/10.1002\/eji.201847924","journal-title":"Eur J Immunol"},{"issue":"3","key":"2636_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/all.13635","volume":"74","author":"R Bianchini","year":"2019","unstructured":"Bianchini R, Roth-Walter F, Ohradanova-Repic A, Flicker S, Hufnagl K, Fischer MB et al (2019) IgG4 drives M2a macrophages to a regulatory M2b-like phenotype: potential implication in immune tolerance. Allergy 74(3):483\u2013494. https:\/\/doi.org\/10.1111\/all.13635","journal-title":"Allergy"},{"issue":"6","key":"2636_CR18","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.4161\/19420862.2014.975657","volume":"6","author":"JF Swisher","year":"2014","unstructured":"Swisher JF, Haddad DA, McGrath AG, Boekhoudt GH, Feldman GM (2014) IgG4 can induce an M2-like phenotype in human monocyte-derived macrophages through FcgammaRI. MAbs 6(6):1377\u20131384. https:\/\/doi.org\/10.4161\/19420862.2014.975657","journal-title":"MAbs"},{"issue":"7","key":"2636_CR19","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang T, Song X, Xu L, Ma J, Zhang Y, Gong W et al (2018) The binding of an anti-PD-1 antibody to FcgammaRIota has a profound impact on its biological functions. Cancer Immunol Immunother 67(7):1079\u20131090. https:\/\/doi.org\/10.1007\/s00262-018-2160-x","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2636_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2249.2004.02566.x","volume":"138","author":"M Holland","year":"2004","unstructured":"Holland M, Hewins P, Goodall M, Adu D, Jefferis R, Savage CO (2004) Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener\u2019s granulomatosis: a possible pathogenic role for the IgG4 subclass. Clin Exp Immunol 138(1):183\u2013192. https:\/\/doi.org\/10.1111\/j.1365-2249.2004.02566.x","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"2636_CR21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","volume":"25","author":"G Lo Russo","year":"2019","unstructured":"Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G et al (2019) Antibody-Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade. Clin Cancer Res 25(3):989\u2013999. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1390","journal-title":"Clin Cancer Res"},{"issue":"389","key":"2636_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aal3604","volume":"9","author":"SP Arlauckas","year":"2017","unstructured":"Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS et al (2017) In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med 9(389):1\u201310. https:\/\/doi.org\/10.1126\/scitranslmed.aal3604","journal-title":"Sci Transl Med"},{"issue":"3","key":"2636_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","volume":"28","author":"R Dahan","year":"2015","unstructured":"Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV (2015) FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis. Cancer Cell 28(3):285\u2013295. https:\/\/doi.org\/10.1016\/j.ccell.2015.08.004","journal-title":"Cancer Cell"},{"issue":"1","key":"2636_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.xphs.2019.10.036","volume":"109","author":"H Kang","year":"2019","unstructured":"Kang H, Larson NR, White DR, Middaugh CR, Tolbert T, Schoneich C (2019) Effects of glycan structure on the stability and receptor binding of an IgG4-Fc. J Pharm Sci 109(1):677\u2013689. https:\/\/doi.org\/10.1016\/j.xphs.2019.10.036","journal-title":"J Pharm Sci"},{"issue":"December","key":"2636_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.aca.2019.08.044","volume":"1089","author":"BL Duivelshof","year":"2019","unstructured":"Duivelshof BL, Jiskoot W, Beck A, Veuthey JL, Guillarme D, D'Atri V (2019) Glycosylation of biosimilars: recent advances in analytical characterization and clinical implications. Anal Chim Acta 1089(December):1\u201318. https:\/\/doi.org\/10.1016\/j.aca.2019.08.044","journal-title":"Anal Chim Acta"},{"issue":"9","key":"2636_CR26","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s41591-019-0568-2","volume":"25","author":"A Cassotta","year":"2019","unstructured":"Cassotta A, Mikol V, Bertrand T, Pouzieux S, Le Parc J, Ferrari P et al (2019) A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients. Nat Med 25(9):1402\u20131407. https:\/\/doi.org\/10.1038\/s41591-019-0568-2","journal-title":"Nat Med"},{"issue":"50","key":"2636_CR27","doi-asserted-by":"publisher","first-page":"34482","DOI":"10.1074\/jbc.M114.615500","volume":"289","author":"PA van Schouwenburg","year":"2014","unstructured":"van Schouwenburg PA, Kruithof S, Votsmeier C, van Schie K, Hart MH, de Jong RN et al (2014) Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J Biol Chem 289(50):34482\u201334488. https:\/\/doi.org\/10.1074\/jbc.M114.615500","journal-title":"J Biol Chem"},{"issue":"2","key":"2636_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/ard.2006.057406","volume":"66","author":"CJ van der Laken","year":"2007","unstructured":"van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G et al (2007) Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 66(2):253\u2013256. https:\/\/doi.org\/10.1136\/ard.2006.057406","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2636_CR29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/FTD.0000000000000553","volume":"40","author":"BD Hock","year":"2018","unstructured":"Hock BD, McKenzie JL, Goddard L, Smith SM, McEntyre CJ, Keating PE (2018) Discrimination of anti-drug antibodies with neutralizing capacity in infliximab- and adalimumab-treated patients: comparison of the homogeneous mobility shift assay and the affinity capture and elution assay. Ther Drug Monit 40(6):705\u2013715. https:\/\/doi.org\/10.1097\/FTD.0000000000000553","journal-title":"Ther Drug Monit"},{"issue":"1","key":"2636_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/FTD.0000000000000229","volume":"38","author":"BD Hock","year":"2016","unstructured":"Hock BD, Stamp LK, Hayman MW, Keating PE, Helms ET, Barclay ML (2016) Development of an ELISA-based competitive binding assay for the analysis of drug concentration and antidrug antibody levels in patients receiving adalimumab or infliximab. Ther Drug Monit 38(1):32\u201341. https:\/\/doi.org\/10.1097\/FTD.0000000000000229","journal-title":"Ther Drug Monit"},{"issue":"7","key":"2636_CR31","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.4049\/jimmunol.143.7.2401","volume":"143","author":"DT Harris","year":"1989","unstructured":"Harris DT, Travis WW, Koren HS (1989) Induction of activation antigens on human natural killer cells mediated through the Fc-gamma receptor. J Immunol 143(7):2401\u20132406","journal-title":"J Immunol"},{"issue":"2","key":"2636_CR32","doi-asserted-by":"publisher","first-page":"e1381813","DOI":"10.1080\/2162402X.2017.1381813","volume":"7","author":"MC Duggan","year":"2018","unstructured":"Duggan MC, Campbell AR, McMichael EL, Opheim KS, Levine KM, Bhave N et al (2018) Co-stimulation of the Fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25. Oncoimmunology 7(2):e1381813. https:\/\/doi.org\/10.1080\/2162402X.2017.1381813","journal-title":"Oncoimmunology"},{"issue":"9","key":"2636_CR33","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1083\/jcb.201712085","volume":"217","author":"K Srpan","year":"2018","unstructured":"Srpan K, Ambrose A, Karampatzakis A, Saeed M, Cartwright ANR, Guldevall K et al (2018) Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells. J Cell Biol 217(9):3267\u20133283. https:\/\/doi.org\/10.1083\/jcb.201712085","journal-title":"J Cell Biol"},{"issue":"19","key":"2636_CR34","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1158\/0008-5472.CAN-15-0781","volume":"75","author":"C Capuano","year":"2015","unstructured":"Capuano C, Romanelli M, Pighi C, Cimino G, Rago A, Molfetta R et al (2015) Anti-CD20 therapy acts via FcgammaRIIIA to diminish responsiveness of human natural killer cells. Cancer Res 75(19):4097\u20134108. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0781","journal-title":"Cancer Res"},{"issue":"2","key":"2636_CR35","doi-asserted-by":"publisher","first-page":"e87379","DOI":"10.1172\/jci.insight.87379","volume":"2","author":"RJ Popat","year":"2017","unstructured":"Popat RJ, Hakki S, Thakker A, Coughlan AM, Watson J, Little MA et al (2017) Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development. JCI Insight 2(2):e87379. https:\/\/doi.org\/10.1172\/jci.insight.87379","journal-title":"JCI Insight"},{"issue":"11","key":"2636_CR36","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1111\/all.13471","volume":"73","author":"A Vultaggio","year":"2018","unstructured":"Vultaggio A, Nencini F, Carraresi A, Pratesi S, Moverare R, Eriksson C et al (2018) IgG4 anti-infliximab in treated patients: clinical impact and temporal evolution. Allergy 73(11):2172\u20132181. https:\/\/doi.org\/10.1111\/all.13471","journal-title":"Allergy"},{"issue":"6","key":"2636_CR37","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ajg.2013.12","volume":"108","author":"N Vande Casteele","year":"2013","unstructured":"Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P et al (2013) Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 108(6):962\u2013971. https:\/\/doi.org\/10.1038\/ajg.2013.12","journal-title":"Am J Gastroenterol"},{"issue":"16","key":"2636_CR38","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.4155\/bio-2018-0091","volume":"10","author":"D Egging","year":"2018","unstructured":"Egging D, Verhagen J, Laat-Arts K, Wit B, Boekel TV, Buurman M et al (2018) Sensitivity and drug tolerance of antidrug antibody assays in relation to positive control characteristics. Bioanalysis 10(16):1289\u20131306. https:\/\/doi.org\/10.4155\/bio-2018-0091","journal-title":"Bioanalysis"},{"issue":"4","key":"2636_CR39","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s11095-014-1541-x","volume":"32","author":"M Ahmadi","year":"2015","unstructured":"Ahmadi M, Bryson CJ, Cloake EA, Welch K, Filipe V, Romeijn S et al (2015) Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharm Res 32(4):1383\u20131394. https:\/\/doi.org\/10.1007\/s11095-014-1541-x","journal-title":"Pharm Res"},{"issue":"8","key":"2636_CR40","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.4049\/jimmunol.1100244","volume":"188","author":"IN Shalova","year":"2012","unstructured":"Shalova IN, Kajiji T, Lim JY, Gomez-Pina V, Fernandez-Ruiz I, Arnalich F et al (2012) CD16 regulates TRIF-dependent TLR4 response in human monocytes and their subsets. J Immunol 188(8):3584\u20133593. https:\/\/doi.org\/10.4049\/jimmunol.1100244","journal-title":"J Immunol"},{"issue":"18","key":"2636_CR41","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1158\/0008-5472.CAN-19-0053","volume":"79","author":"V Fleming","year":"2019","unstructured":"Fleming V, Hu X, Weller C, Weber R, Groth C, Riester Z et al (2019) Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. Cancer Res 79(18):4715\u20134728. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0053","journal-title":"Cancer Res"},{"issue":"1\u201351","key":"2636_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0452-5","volume":"6","author":"ZF Wen","year":"2018","unstructured":"Wen ZF, Liu H, Gao R, Zhou M, Ma J, Zhang Y et al (2018) Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1. J Immunother Cancer 6(1\u201351):1\u201316. https:\/\/doi.org\/10.1186\/s40425-018-0452-5","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2636_CR43","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1158\/2326-6066.CIR-17-0550","volume":"6","author":"JHW Pahl","year":"2018","unstructured":"Pahl JHW, Koch J, Gotz JJ, Arnold A, Reusch U, Gantke T et al (2018) CD16A activation of NK cells promotes NK cell proliferation and memory-like cytotoxicity against cancer cells. Cancer Immunol Res 6(5):517\u2013527. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0550","journal-title":"Cancer Immunol Res"},{"issue":"129","key":"2636_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-019-2661-0","volume":"36","author":"E Hoffmann","year":"2019","unstructured":"Hoffmann E, Jordan G, Lauer M, Ringler P, Kusznir EA, Rufer AC et al (2019) Generation, characterization, and quantitative bioanalysis of drug\/anti-drug antibody immune complexes to facilitate dedicated in vivo studies. Pharm Res 36(129):1\u201315. https:\/\/doi.org\/10.1007\/s11095-019-2661-0","journal-title":"Pharm Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02636-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02636-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02636-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T13:41:00Z","timestamp":1696254060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02636-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2636"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02636-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"19 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the Northern B Health and Disability Ethics Committee, New Zealand (Approval # 16\/NTB\/139).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"All patients and healthy blood donors gave written informed consent prior to blood sample collection.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}